SG10201912150TA - Anti-trem2 antibodies and methods of use thereof - Google Patents
Anti-trem2 antibodies and methods of use thereofInfo
- Publication number
- SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238044P | 2015-10-06 | 2015-10-06 | |
| US201662369666P | 2016-08-01 | 2016-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912150TA true SG10201912150TA (en) | 2020-02-27 |
Family
ID=57178515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912150TA SG10201912150TA (en) | 2015-10-06 | 2016-10-06 | Anti-trem2 antibodies and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330335A1 (enExample) |
| EP (1) | EP3359569A2 (enExample) |
| JP (2) | JP7725185B2 (enExample) |
| KR (1) | KR20180068999A (enExample) |
| CN (2) | CN108738323B (enExample) |
| AU (2) | AU2016334051B2 (enExample) |
| CA (1) | CA2997960A1 (enExample) |
| SG (1) | SG10201912150TA (enExample) |
| WO (1) | WO2017062672A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689904A1 (en) | 2013-03-13 | 2020-08-05 | Prothena Biosciences Limited | Tau immunotherapy |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MX2017001531A (es) | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| US10428143B2 (en) | 2014-09-28 | 2019-10-01 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR102750101B1 (ko) | 2016-05-02 | 2025-01-03 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7481726B2 (ja) | 2016-05-02 | 2024-05-13 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| US10941200B2 (en) | 2016-07-22 | 2021-03-09 | Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev | TREM2 cleavage modulators and uses thereof |
| US12138069B2 (en) * | 2016-12-13 | 2024-11-12 | Akili Interactive Labs, Inc. | Platform for identification of biomarkers using navigation tasks and treatments using navigation tasks |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| US11584790B2 (en) | 2017-04-14 | 2023-02-21 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| PE20200695A1 (es) | 2017-05-02 | 2020-06-16 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CA3068256A1 (en) * | 2017-06-21 | 2018-12-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| RS64419B1 (sr) | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 antitela i postupci za njihovu upotrebu |
| US20200277373A1 (en) * | 2017-09-14 | 2020-09-03 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| US10829547B2 (en) * | 2017-10-16 | 2020-11-10 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| EP3723803A4 (en) * | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CA3100398A1 (en) * | 2018-05-18 | 2019-11-21 | Macrogenics, Inc. | Optimized gp41-binding molecules and uses thereof |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| CA3111569A1 (en) * | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| EP3861018A4 (en) * | 2018-10-05 | 2022-10-26 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | NEWBORN SCREENING FOR PRIMARY IMMUNODEFICIENCIES, CYSTINOSIS AND WILSON'S DISEASE |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| SG11202103568PA (en) * | 2018-10-23 | 2021-05-28 | Magenta Therapeutics Inc | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| KR102156165B1 (ko) * | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
| US12351629B2 (en) | 2018-12-10 | 2025-07-08 | Mor Research Applications Ltd. | TREM2 antibodies and uses thereof |
| CN113194994B (zh) * | 2018-12-11 | 2025-11-28 | 开拓免疫医疗公司 | 使用抗trem2抗体的方法 |
| CN113597431B (zh) * | 2019-02-08 | 2025-02-21 | 普罗塞纳生物科学有限公司 | 识别Tau的抗体 |
| EP3927743A1 (en) * | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| EP3931349B8 (en) * | 2019-02-28 | 2025-01-15 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
| PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CN110320368A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021101823A1 (en) * | 2019-11-22 | 2021-05-27 | Eli Lilly And Company | Trem2 antibodies and uses thereof |
| WO2021113655A1 (en) | 2019-12-05 | 2021-06-10 | Alector Llc | Methods of use of anti-trem2 antibodies |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| CN115279790A (zh) * | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| CA3167851A1 (en) * | 2020-02-24 | 2021-09-02 | Francesca CIGNARELLA | Methods of use of anti-trem2 antibodies |
| EP4574971A2 (en) | 2020-03-31 | 2025-06-25 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| EP4126953A2 (en) * | 2020-04-03 | 2023-02-08 | Alector LLC | Methods of use of anti-trem2 antibodies |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| CN115803341A (zh) * | 2020-06-26 | 2023-03-14 | 生命北极公司 | 结合α-突触核蛋白原纤维的抗体 |
| JP2023536916A (ja) * | 2020-08-05 | 2023-08-30 | ビジル・ニューロサイエンス・インコーポレイテッド | Ｔｒｅｍ２アゴニストを使用した、コロニー刺激因子１受容体機能不全に関連する疾患の治療 |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
| WO2022115705A2 (en) | 2020-11-30 | 2022-06-02 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| CN117015400A (zh) * | 2020-12-04 | 2023-11-07 | 维吉尔神经科学股份有限公司 | 使用trem2激动剂治疗与atp结合盒转运体1功能障碍有关的疾病 |
| EP4281112A4 (en) * | 2021-01-21 | 2025-01-15 | Twist Bioscience Corporation | METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS |
| CN112979795B (zh) * | 2021-02-26 | 2022-07-08 | 深圳市亚辉龙生物科技股份有限公司 | 抗体组合产品及其在新冠肺炎检测中应用 |
| US11904020B2 (en) * | 2021-03-19 | 2024-02-20 | Bicycletx Limited | Bicyclic peptide ligands specific for TREM2 |
| TW202306993A (zh) | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Ｔｒｅｍ２之促效劑 |
| EP4351618A4 (en) * | 2021-05-19 | 2025-09-24 | Signablok Inc | TREM-2/DAP-12 INHIBITORS FOR TREATING LUNG DISEASES AND INJURIES AND COMBINATIONS THEREOF |
| JP2024531426A (ja) * | 2021-08-20 | 2024-08-29 | タスリフ ファーマシューティカル，エルエルシー | Ｃｄ１５５に対する抗体および抗原結合フラグメント、その使用方法 |
| WO2023039450A2 (en) * | 2021-09-07 | 2023-03-16 | Duke University | Compositions and methods for treatment of retinal degeneration |
| EP4429663A4 (en) * | 2021-11-09 | 2025-09-17 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS USED AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 |
| TW202340235A (zh) | 2021-12-17 | 2023-10-16 | 美商戴納立製藥公司 | 多肽工程、文庫及工程ｃｄ９８重鏈以及轉鐵蛋白受體結合多肽 |
| EP4463484A2 (en) * | 2022-01-14 | 2024-11-20 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| EP4482523A1 (en) | 2022-02-23 | 2025-01-01 | Alector LLC | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| US20250289879A1 (en) * | 2022-04-29 | 2025-09-18 | The Children's Medical Center Corporation | Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024182318A2 (en) * | 2023-02-28 | 2024-09-06 | Kodiak Sciences Inc. | Antibodies to htra1 and conjugates thereof |
| WO2024226569A1 (en) * | 2023-04-24 | 2024-10-31 | The Research Foundation For The State University Of New York | Immunogenicity screening method |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| CN119874909B (zh) * | 2023-12-21 | 2025-11-04 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025194147A1 (en) * | 2024-03-15 | 2025-09-18 | The Children's Medical Center Corporation | Therapeutic modulation of trem2 and uses thereof in retinal degeneration |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| JP2004073182A (ja) | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| CA2506672C (en) | 2002-12-23 | 2012-04-17 | Schering Corporation | Il-23 for treating cutaneous wounds |
| US20080181888A1 (en) | 2004-12-31 | 2008-07-31 | Ambrose Christine M | Polypeptides That Bind Br3 and Uses Thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2007106585A1 (en) | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CN101855242B (zh) | 2007-09-14 | 2014-07-30 | 阿迪马布有限责任公司 | 合理设计的合成抗体文库及其用途 |
| EP2195344A4 (en) | 2007-10-05 | 2011-07-06 | Univ Maryland | NEW COMPOSITIONS AND METHODS FOR STIMULATING ERYTHROPOIESE IN A MAMMALIAN |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US10584181B2 (en) * | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| MX2017001531A (es) | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
-
2016
- 2016-10-06 JP JP2018517785A patent/JP7725185B2/ja active Active
- 2016-10-06 CN CN201680070761.1A patent/CN108738323B/zh active Active
- 2016-10-06 WO PCT/US2016/055828 patent/WO2017062672A2/en not_active Ceased
- 2016-10-06 AU AU2016334051A patent/AU2016334051B2/en active Active
- 2016-10-06 CA CA2997960A patent/CA2997960A1/en active Pending
- 2016-10-06 CN CN202310465565.6A patent/CN117069841A/zh active Pending
- 2016-10-06 SG SG10201912150TA patent/SG10201912150TA/en unknown
- 2016-10-06 US US15/766,363 patent/US20190330335A1/en not_active Abandoned
- 2016-10-06 KR KR1020187012495A patent/KR20180068999A/ko not_active Ceased
- 2016-10-06 EP EP16784666.6A patent/EP3359569A2/en active Pending
-
2023
- 2023-02-17 US US18/171,291 patent/US20230295297A1/en active Pending
- 2023-04-04 JP JP2023060952A patent/JP2023093528A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200443A patent/AU2024200443A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230295297A1 (en) | 2023-09-21 |
| CN108738323B (zh) | 2023-05-26 |
| US20190330335A1 (en) | 2019-10-31 |
| JP7725185B2 (ja) | 2025-08-19 |
| AU2024200443A1 (en) | 2024-04-04 |
| WO2017062672A2 (en) | 2017-04-13 |
| WO2017062672A3 (en) | 2017-05-26 |
| CN117069841A (zh) | 2023-11-17 |
| KR20180068999A (ko) | 2018-06-22 |
| CN108738323A (zh) | 2018-11-02 |
| EP3359569A2 (en) | 2018-08-15 |
| AU2016334051B2 (en) | 2023-10-26 |
| AU2016334051A1 (en) | 2018-04-12 |
| JP2018537956A (ja) | 2018-12-27 |
| CA2997960A1 (en) | 2017-04-13 |
| JP2023093528A (ja) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL257636A (en) | Anti-tigit antibodies and methods of use | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| SG11201803567XA (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL259681A (en) | New antibodies against claudin and methods of using them | |
| ZA202001985B (en) | Anti-htra1 antibodies and methods of use thereof | |
| ES3049257T3 (en) | Anti-c1s antibodies and methods of use thereof |